{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:18:58Z","timestamp":1791019138684,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00520-007-0318-8","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T10:00:46Z","timestamp":1186394446000},"page":"267-273","source":"Crossref","is-referenced-by-count":61,"title":["Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women\u2019s cancers. Results of a prospective study"],"prefix":"10.1007","volume":"16","author":[{"given":"Mark","family":"Hackbarth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Lichtenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,7]]},"reference":[{"key":"318_CR1","doi-asserted-by":"crossref","unstructured":"Anonymous (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 16(11):3537\u20133541","DOI":"10.1200\/JCO.1998.16.11.3537"},{"issue":"6","key":"318_CR2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0959-8049(96)00497-2","volume":"33","author":"S Chiara","year":"1997","unstructured":"Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R (1997) Hand\u2013foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 33(6):967\u2013969","journal-title":"Eur J Cancer"},{"issue":"5","key":"318_CR3","first-page":"508","volume":"87","author":"S Chiewchanvit","year":"2004","unstructured":"Chiewchanvit S, Noppakun K, Kanchanarattanakorn K (2004) Mucocutaneous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thail 87(5):508\u2013514","journal-title":"J Med Assoc Thail"},{"issue":"4","key":"318_CR4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1365-2133.2000.03432.x","volume":"142","author":"CY Chu","year":"2000","unstructured":"Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC (2000) Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142(4):808\u2013811","journal-title":"Br J Dermatol"},{"issue":"5C","key":"318_CR5","first-page":"1781","volume":"13","author":"A Comandone","year":"1993","unstructured":"Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar\u2013plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13(5C):1781\u20131783","journal-title":"Anticancer Res"},{"issue":"5","key":"318_CR6","first-page":"501","volume":"19","author":"JD DeSpain","year":"1992","unstructured":"DeSpain JD (1992) Dermatologic toxicity of chemotherapy. Semin Oncol 19(5):501\u2013507","journal-title":"Semin Oncol"},{"issue":"2","key":"318_CR7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL (2004) Oral dexamethasone attenuates doxil-induced palmar\u2013plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94(2):320\u2013324","journal-title":"Gynecol Oncol"},{"key":"318_CR8","unstructured":"EORTC (2006) EORTC QLQ-C30 Questionnaire V3.0"},{"key":"318_CR9","unstructured":"Essex (2000) Caelyx, Wissenschaftliche Produktinformationen"},{"issue":"1","key":"318_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0560.1993.tb01242.x","volume":"20","author":"JE Fitzpatrick","year":"1993","unstructured":"Fitzpatrick JE (1993) The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20(1):1\u201314","journal-title":"J Cutan Pathol"},{"issue":"5","key":"318_CR11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1345\/aph.18307","volume":"33","author":"SM Flory","year":"1999","unstructured":"Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB (1999) Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 33(5):584\u2013586","journal-title":"Ann Pharmacother"},{"issue":"4","key":"318_CR12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","volume":"19","author":"AA Gabizon","year":"2001","unstructured":"Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19(4):424\u2013436","journal-title":"Cancer Invest"},{"issue":"14","key":"318_CR13","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"17","key":"318_CR14","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093\u20133100","journal-title":"J Clin Oncol"},{"issue":"8","key":"318_CR15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H","volume":"75","author":"KB Gordon","year":"1995","unstructured":"Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand\u2013foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75(8):2169\u20132173","journal-title":"Cancer"},{"issue":"10","key":"318_CR16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1012522120294","volume":"12","author":"S Halford","year":"2001","unstructured":"Halford S, Yip D, Karapetis CS, Strickland AH, Steger A, Khawaja HT, Harper PG (2001) A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12(10):1399\u20131402","journal-title":"Ann Oncol"},{"issue":"10","key":"318_CR17","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1177\/0091270004268321","volume":"44","author":"YS Heo","year":"2004","unstructured":"Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK (2004) Hand\u2013foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44(10):1166\u20131172","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"318_CR18","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#","volume":"88","author":"S Hussain","year":"2000","unstructured":"Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 88(10):2367\u20132371","journal-title":"Cancer"},{"key":"318_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/gyno.2000.5819","volume":"78","author":"VP Israel","year":"1999","unstructured":"Israel VP, Garcia A, Roman L, Muderspach L (1999) Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 78:143\u2013147","journal-title":"Gynecol Oncol"},{"issue":"1","key":"318_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0923-1811(00)00106-7","volume":"25","author":"B Korac","year":"2001","unstructured":"Korac B, Buzadzic B (2001) Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J Dermatol Sci 25(1):45\u201352","journal-title":"J Dermatol Sci"},{"issue":"3","key":"318_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00873811","volume":"13","author":"CJ Link Jr","year":"1995","unstructured":"Link CJ Jr, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E (1995) Cutaneous manifestations of Taxol therapy. Invest New Drugs 13(3):261\u2013263","journal-title":"Invest New Drugs"},{"issue":"4","key":"318_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","volume":"44","author":"AM Lopez","year":"1999","unstructured":"Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar\u2013plantar erythrodysesthesia. Cancer Chemother Pharmacol 44(4):303\u2013306","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"318_CR23","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","volume":"136","author":"M Lotem","year":"2000","unstructured":"Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136(12):1475\u20131480","journal-title":"Arch Dermatol"},{"issue":"2","key":"318_CR24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0959-8049(95)00570-6","volume":"32A","author":"A Makris","year":"1996","unstructured":"Makris A, Mortimer P, Powles TJ (1996) Chemotherapy-induced onycholysis. Eur J Cancer 32A(2):374\u2013375","journal-title":"Eur J Cancer"},{"issue":"2","key":"318_CR25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","volume":"93","author":"KL Molpus","year":"2004","unstructured":"Molpus KL, Anderson LB, Craig CL, Puleo JG (2004) The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93(2):513\u2013516","journal-title":"Gynecol Oncol"},{"issue":"3","key":"318_CR26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","volume":"15","author":"FM Muggia","year":"1997","unstructured":"Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15(3):987\u2013993","journal-title":"J Clin Oncol"},{"key":"318_CR27","unstructured":"NCI (1999) Common Toxicity Criteria, Version 2.0. 2.0 ed: http:\/\/ctep.info.nih.gov"},{"issue":"2","key":"318_CR28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1023\/A:1008218824342","volume":"9","author":"A Obermair","year":"1998","unstructured":"Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230\u2013231","journal-title":"Ann Oncol"},{"issue":"3","key":"318_CR29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/annonc\/mdl456","volume":"18","author":"G Oskay-Oezcelik","year":"2007","unstructured":"Oskay-Oezcelik G, Lehmacher W, K\u00f6nsgen D, Christ H, Kaufmann M, Lichtenegger W, Sehouli J (2007) Breast cancer patients\u2019 expectations in respect of the physician\u2013patient relationship and treatment management results of a survey of 617 patients. Ann Oncol 18(3):479\u2013484","journal-title":"Ann Oncol"},{"issue":"11","key":"318_CR30","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdg446","volume":"14","author":"YH Park","year":"2003","unstructured":"Park YH, Ryoo BY, Lee HJ, Kim SA, Chung JH (2003) High incidence of severe hand\u2013foot syndrome during capecitabine\u2013docetaxel combination chemotherapy. Ann Oncol 14(11):1691\u20131692","journal-title":"Ann Oncol"},{"issue":"2","key":"318_CR31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","volume":"82","author":"PG Rose","year":"2001","unstructured":"Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82(2):323\u2013328","journal-title":"Gynecol Oncol"},{"issue":"40","key":"318_CR32","first-page":"1413","volume":"130","author":"M Salzberg","year":"2000","unstructured":"Salzberg M, Herrmann R (2000) Hand\u2013foot syndrome (palmar\u2013plantar erythrodysesthesia). Schweiz Med Wochenschr 130(40):1413\u20131416","journal-title":"Schweiz Med Wochenschr"},{"key":"318_CR33","doi-asserted-by":"crossref","unstructured":"Sehouli J, Oskay-Oezcelik G (2004) Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer. ASCO 2004","DOI":"10.1200\/jco.2004.22.90140.5072"},{"issue":"1","key":"318_CR34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1010679127390","volume":"66","author":"CH Smorenburg","year":"2001","unstructured":"Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66(1):83\u201387","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"318_CR35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","volume":"40","author":"WS Susser","year":"1999","unstructured":"Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999) Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40(3):367\u2013398 (quiz 399\u2013400)","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"318_CR36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","volume":"2","author":"T Tejada-Berges","year":"2002","unstructured":"Tejada-Berges T, Granai CO, Gordinier M, Gajewski W (2002) Caelyx\/doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2(2):143\u2013150","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-007-0318-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0318-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T18:00:34Z","timestamp":1684000834000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-007-0318-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s00520-007-0318-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]}}}